ArticleNeuropsychiatric disease and treatment2026
Echinocystic Acid Antagonizes Post-Stroke Depression in Mice by Suppressing the JNK/NF-κB Signaling Pathway.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-stroke depression (PSD), a common neuropsychiatric complication after stroke, affects approximately one-third of stroke survivors and severely impairs recovery and quality of life. Echinocystic acid (EA), a pentacyclic triterpenoid from various medicinal herbs, exhibits anti-inflammatory and anti-depressant properties. However, whether EA exerts neuroprotective and antidepressant effects in PSD remains unknown. Objective: This study aims to determine whether EA alleviates PSD and to explore its potential mechanisms involving the JNK/NF-κB pathway and inflammatory cytokines. Methods: PSD was modeled using middle cerebral artery occlusion/reperfusion (MCAO/R) combined with chronic unpredictable mild stress (CUMS). Following MCAO/R surgery, animals received daily intraperitoneal injections of EA or EA combined with the JNK agonist anisomycin (AN) for 28 consecutive days. The expression of phosphorylated JNK (p-JNK) and phosphorylated NF-κB (p-NF-κB) was analyzed by Western blotting. The levels of inflammatory cytokines, including IL-1β, IL-6, and TNF-α, were measured using enzyme-linked immunosorbent assay (ELISA). Depressive-like behaviors and the therapeutic efficacy of EA were assessed through a series of behavioral tests. Furthermore, neuronal necrosis and Nissl body integrity were observed using hematoxylin-eosin (H&E) and Nissl staining, respectively. Results: EA treatment significantly downregulated the expression of p-JNK, p-NF-κB, and inflammatory cytokines. H&E staining revealed that EA reduced neuronal necrosis in the hippocampal dentate gyrus. Consistently, Nissl staining demonstrated that EA increased the number of Nissl bodies in the same region. Furthermore, EA administration alleviated depressive-like behaviors in PSD mice. However, the administration of AN counteracted the suppressive effects of EA on the JNK/NF-κB signaling pathway and reversed the beneficial behavioral outcomes associated with EA treatment. Conclusion: The results indicate that EA mitigates neuronal necrosis, alleviates depression-like behaviors, and alleviates PSD by suppressing JNK/NF-κB pathway activation and inflammatory cytokine production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.